Ranked on: #5 Top Health & Biotech Startups 2026 · #46 Largest Series C+ Rounds of 2026 (Ranked) · Get your badge →
Is this your company? Get featured or correct your listing →
Key Metrics
Company Snapshot
Chai Discovery is a Biotech company, based in San Francisco, California, USA, founded 2024 by Joshua Meier, Matthew McPartlon, Jack Dent. Latest valuation $3.8B (As of Jul 17, 2026, Crunchbase News).
Recent changes
- Jul 17, 2026Jul 17, 2026First reported valuation: $3.8B Crunchbase News
- Jul 17, 2026Jul 17, 2026Chai Discovery Raises $400M at $3.8B for AI Drug Design Pulse story
- Jul 14, 2026Jul 14, 2026Raised $400M Series C at a $3.8B valuation Law360
- Jul 14, 2026Jul 14, 2026New investor: Index Ventures Law360
- Jul 14, 2026Jul 14, 2026New investor: Sapphire Ventures Law360
Earlier changes (9)
- Jul 14, 2026Jul 14, 2026New investor: Menlo Ventures Law360
- Jul 14, 2026Jul 14, 2026New investor: Sequoia Capital Law360
- Jul 14, 2026Jul 14, 2026New investor: Battery Ventures Law360
- Jul 14, 2026Jul 14, 2026New investor: Dimension Law360
- Jul 14, 2026Jul 14, 2026New investor: Bain Capital Ventures Law360
- Jul 14, 2026Jul 14, 2026New investor: Kleiner Perkins Law360
- Jul 14, 2026Jul 14, 2026New investor: Baillie Gifford Law360
- Dec 15, 2025Dec 15, 2025Raised $130M Series B parlournews.com
- Dec 15, 2025Dec 15, 2025New investor: General Catalyst parlournews.com
Funding History
2 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jul 14, 2026 | Series C | $400M | $3.8B | Index VenturesLeadCrunchbase NewsKleiner PerkinsCrunchbase NewsSequoia CapitalCrunchbase NewsDimensionCrunchbase NewsBaillie GiffordunverifiedBain Capital VenturesunverifiedBattery VenturesunverifiedMenlo VenturesunverifiedSapphire Venturesunverified | Law360 |
| Dec 15, 2025 | Series B | $130M | — | General CatalystunverifiedOak HC/FT | parlournews.com |
Investors
Latest Pulse
- Aug 31, 2026Biotech Funding Held Its Ground While AI Took the OxygenGlobal biotech startup investment is tracking to its usual $36 billion to $40 billion range in 2026 despite the AI capital surge, with more than $6 billion of that going to AI-native drug discovery companies.→
- Aug 20, 2026Colossal Spinout Astromech Hits $3.8B on Biology AIAstromech, a Colossal Biosciences spinout co-founded by Ben Lamm and George Church, raised $20M at a $3.8B valuation to build AI models that predict evolutionary biological change.→
- Aug 20, 2026Claude Designed Working Protein Binders in a Lab TestAnthropic says Claude generated functional protein binders for 14 of 15 biological targets in a lab test run with Adaptyv Bio and Twist Bioscience, beating typical industry hit rates by roughly 2x.→
- Aug 13, 2026Bridge to Life Raises $110M for Organ PreservationBridge to Life closed $110 million in Series C equity funding plus additional debt financing for its organ preservation and perfusion technology, part of a broader wave of biotech capital chasing transplant and longevity-adjacent medtech in 2026.→
- Jul 21, 2026Dimension Capital Closes $800M Fund for Science and AIDimension Capital raised an $800 million third fund, 60% larger than its prior vehicle, betting that founders increasingly want to build companies crossing the boundary between biotech, physical science and AI compute.→
- Jul 21, 2026Dimension Capital Raises $800M Third Fund for Science-Compute BetsDimension Capital closed an $800 million third fund, 60% larger than its prior vehicle, betting on the intersection of biotech and AI compute after early wins including Chai Discovery's jump to a $3.8 billion valuation.→
- Jul 17, 2026Chai Discovery Raises $400M at $3.8B for AI Drug DesignLife-sciences AI startup Chai Discovery raised a $400 million Series C at a $3.8 billion valuation led by Index Ventures, with Sequoia, Dimension and Kleiner Perkins participating, one of the largest rounds yet for AI-driven drug and molecule design.→
Coverage Timeline
newest firstAll Coverage
FUNDING$800M Fund III
Dimension Capital Raises $800M Third Fund for Science-Compute Bets
Dimension Capital closed an $800 million third fund, 60% larger than its prior vehicle, betting on the intersection of biotech and AI compute after early wins including Chai Discovery's jump to a $3.8 billion valuation.
Chai Discovery Raises $400M at $3.8B for AI Drug Design
FUNDING$400M at $3.8B
Chai Discovery Raises $400M at $3.8B for AI Drug Design
Life-sciences AI startup Chai Discovery raised a $400 million Series C at a $3.8 billion valuation led by Index Ventures, with Sequoia, Dimension and Kleiner Perkins participating, one of the largest rounds yet for AI-driven drug and molecule design.
Value Add Research
- VC & Investing · Jul 15, 2026$400M at $3.8B — Chai Discovery AI Drug Design
- Market & Trends · Oct 15, 2026Q3 2026 Health & Biotech Funding Rounds: Chai's $400M
- AI & Technology · Oct 9, 2026Iambic Therapeutics IPO: $150M Raise, $758M Valuation Eyed
- VC & Investing · Sep 7, 2026Menlo Ventures 2026: $3B Fund, $14B Anthropic Stake, New Deals
- Market & Trends · Jul 10, 2026$5B+ Raised — AI Drug Discovery Startups (2026)
Related Companies
Chai Discovery FAQ
What is Chai Discovery's valuation?
Chai Discovery's valuation is $3.8B (As of Jul 17, 2026, Crunchbase News).
Who are Chai Discovery's investors?
Chai Discovery's investors include Index Ventures, Baillie Gifford, Bain Capital Ventures, Battery Ventures, Dimension, and 7 more (As of Jul 17, 2026).
Sources & methodologyshow
Where these figures come from
- Crunchbase Newsresearch database1 fact
- Law360Value Add VC data1 fact
- parlournews.comValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.